29 filings
8-K
PMVP
PMV Pharmaceuticals Inc
29 Feb 24
PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights
4:05pm
8-K
PMVP
PMV Pharmaceuticals Inc
18 Jan 24
PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway
4:02pm
8-K
PMVP
PMV Pharmaceuticals Inc
5 Jan 24
PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development
4:01pm
8-K
PMVP
PMV Pharmaceuticals Inc
9 Nov 23
PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights
8:00am
8-K
PMVP
PMV Pharmaceuticals Inc
12 Oct 23
PMV Pharmaceuticals Updated PC14586 Phase 1 Data
5:02pm
8-K
grebsac5h2t1xc c1p
11 Oct 23
PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference
4:02pm
8-K
jlvk ivdd
9 Aug 23
PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Highlights
8:00am
8-K
ilz1ctouoe25 gun1
9 Jun 23
Submission of Matters to a Vote of Security Holders
8:01am
8-K
kuj7kmqu70gbn0o
10 May 23
PMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Highlights
8:00am
8-K
v2owsl3612hth43
28 Apr 23
Amendments to Articles of Incorporation or Bylaws
8:01am
8-K
s3dcop0p
1 Mar 23
PMV Pharmaceuticals Reports Full Year 2022 Financial Results and Corporate Highlights
8:01am
8-K
lwdkx2zb1vvmxy
8 Nov 22
PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights
8:01am
8-K
kny0yfvy31 d6yn2u
4 Nov 22
PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors
8:00am
8-K
8w1e7f 3mipw3ig
9 Aug 22
PMV Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights
8:00am
8-K
p8ndo3
8 Jun 22
Overall response rate (ORR) of 32% (8/25) achieved in higher dose cohorts per RECIST v1.1
6:07am
8-K
cvqow4w 95qfvu
6 Jun 22
Submission of Matters to a Vote of Security Holders
3:45pm
8-K
rzh63y
26 May 22
Preliminary results represent the first clinical evidence of targeting a p53 Y220C mutation
5:00pm
8-K
n9rqq2
10 May 22
PMV Pharmaceuticals Reports First Quarter 2022 Financial Results and Corporate Highlights
7:15am
8-K
33ul hoq4141h
1 Mar 22
PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
7:15am
8-K
yc39146 zm
6 Jan 22
PMV Pharma Announces Changes to its Board of Directors
8:01am